Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage II-III esophageal carcinoma

Japanese Journal of Clinical Oncology

Volumn 43, Issue 6, 2013, Pages 608-615

  Kato, Ken ^a   Nakajima, Takako Eguchi ^a,b   Ito, Yoshinori ^a   Katada, Chikatoshi ^c   Ishiyama, Hiromichi ^c   Tokunaga, Shin Ya ^d   Tanaka, Masahiro ^d   Hironaka, Shuichi ^e   Hashimoto, Takayuki ^e   Ura, Takashi ^f   Kodaira, Takeshi ^f   Yoshimura, Ken Ichi ^g  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

50.4 Gy; Chemoradiotherapy; Elective nodal irradiation; Esophageal squamous cell carcinoma; Salvage surgery

Indexed keywords

CISPLATIN; FLUOROURACIL;

ACUTE TOXICITY; ADULT; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER STAGING; CHEMORADIOTHERAPY; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LYMPH NODE DISSECTION; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; ORGAN PRESERVATION; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION PNEUMONIA; RECURRENT CANCER; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

50.4 GY; CHEMORADIOTHERAPY; ELECTIVE NODAL IRRADIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; SALVAGE SURGERY;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; FLUOROURACIL; HUMANS; LYMPHATIC IRRADIATION; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878645001     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt048     Document Type: Article

References (30)

1. Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods. Part II. Completeness. Eur J Cancer 2009;45:756-64.
2. Matsuda A, Matsuda T, Shibata A, et al. Cancer incidence and incidence rates in Japan in 2007: based on data from 21 populationbased cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2013;43:328-36.
3. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 2003;21:4592-6.
4. Ando N, Kato H, Igaki H, et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). Ann Surg Oncol 2012;19:68-74.
5. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225-32.
6. Kato K, Muro K, Minashi K, et al. Phase II Study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG Trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2011;81:684-90.
7. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74.
8. Onozawa M, Nihei K, Ishikura S, et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 2009;92:266-9.
9. Nakajima TE, Ura T, Ito Y, et al. A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer. Jpn J Clin Oncol 2009;39:37-42.
10. Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines. Int J Clin Oncol 2004;9(Suppl. 3):1-82.
11. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
12. Kuwano H, Nishimura Y, Ohtsu A, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2007 edition. Esophagus 2008;5:61-73.
13. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-9.
14. McGuill MJ, Byrne P, Ravi N, Reynolds J. The prognostic impact of occult lymph node metastasis in cancer of the esophagus or esophago-gastric junction: systematic review and meta-analysis. Dis Esophagus 2008;21:236-40.
15. Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer 2008;112:1239-46.
16. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991-4008.
17. Friedman DL, Constine LS. Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw 2006;4:249-57.
18. López RM, Cerezo PL. Toxicity associated to radiotherapy treatment in lung cancer patients. Clin Transl Oncol 2007;9:506-12.
19. Morota M, Gomi K, Kozuka T, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 2009;75:122-8.
20. Kumekawa Y, Kaneko K, Ito H, et al. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2006;41: 425-32.
21. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003;21:2697-702.
22. Nakamura T, Hayashi K, Ota M, et al. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg 2004;188:261-6.
23. Hennequin C, Gayet B, Sauvanet A, et al. Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus. Int J Radiat Oncol Biol Phys 2001;49:657-64.
24. Tomimaru Y, Yano M, Takachi K, et al. Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy. J Surg Oncol 2006;93:422-8.
25. Hattori S, Muto M, Ohtsu A, et al. EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc 2003;58:65-70.
26. Wilson KS, Lim JT. Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation. Radiother Oncol 2000;54:129-34.
27. Murakami M, Kuroda Y, Okamoto Y, et al. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 1998;40:1049-59.
28. Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 2002;123:175-83.
29. Meunier B, Raoul J, Le Prise E, Lakéhal M, Launois B. Salvage esophagectomy after unsuccessful curative chemoradiotherapy for squamous cell cancer of the esophagus. Dig Surg 1998;15:224-6.
30. Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2009;137:49-54.